临床药师参与1例尿路感染伴药物热患者药学实践

doi:10.19803/j.1672-8629.2022.05.22

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (5): 572-573.
DOI: 10.19803/j.1672-8629.2022.05.22

临床药师参与1例尿路感染伴药物热患者药学实践

杨宝春, 孙欣, 杨欣, 吴琳, 王丽萍^*

南京医科大学附属无锡第二医院药学部,江苏无锡214000

收稿日期:2020-08-15 出版日期:2022-05-15 发布日期:2022-05-18
通讯作者: * 王丽萍,女,本科,主任药师,医院药学。E-mail：407545601@qq.com
作者简介:杨宝春,女,硕士,主管药师,临床药学与医院药学。
基金资助:
江苏省药学会奥赛康医院药学基金（A2017090）

Pharmaceutical care for a patient with urinary tract infection and drug fever

YANG Baochun, SUN Xin, YANG Xin, WU Lin, WANG Liping^*

Department of Pharmacy, Wuxi Second Hospital, Nanjing Medical University, Wuxi Jiangsu 214000, China

Received:2020-08-15 Online:2022-05-15 Published:2022-05-18

摘要/Abstract

摘要： 目的分析临床药师参与尿路感染患者的用药监护,探讨提高医师和药师对药物热药学实践的认识。方法介绍临床药师参与1例疑似头孢地嗪致药物热患者的用药分析与治疗干预过程。结果临床药师根据药物热发生机制、临床特点,分析患者的临床症状、实验室检查结果和用药情况,建议临床医师停用头孢地嗪后,患者体温逐渐恢复正常。结论临床药师深入临床进行用药监测,可及时发现药品不良反应,防止不合理用药,提高药物的合理使用水平。

关键词: 临床药师, 药物热, 头孢地嗪, 药品不良反应

Abstract: Objective To explore the effect of monitoring of drug use by clinical pharmacists for a patient with urinary tract infection and to advance physicians' and pharmacists' understanding of drug fever. Methods A clinical pharmacist participated in the analysis and intervention of a suspected cefdiazine-induced fever patient. Results Based on the mechanism, clinical characteristics of drug fever, clinical symptoms, laboratory test results and drug use of the patient, the clinical pharmacist suspected that the fever might have been caused by cefdiazine and suggested that cefdiazine be discontinued. The clinician took the advice so that the patient's temperature gradually returned to normal. Conclusion Active participation in drug monitoring by clinical pharmacists will help to detect adverse drug reactions as soon as possible so as to prevent irrational use of drugs.

Key words: clinical pharmacists, drug fever, cefodizime, adverse drug reaction

中图分类号:

R969.3

杨宝春, 孙欣, 杨欣, 吴琳, 王丽萍. 临床药师参与1例尿路感染伴药物热患者药学实践[J]. 中国药物警戒, 2022, 19(5): 572-573.

YANG Baochun, SUN Xin, YANG Xin, WU Lin, WANG Liping. Pharmaceutical care for a patient with urinary tract infection and drug fever[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 572-573.

参考文献

[1] LIU XJ.Practice and experience of clinical pharmacist participating in consultation for drug fever[J]. China Pharmaceuticals(中国药业), 2016, 25(2): 90-91.
[2] TIAN G, WANG X.Role of inflammatory markers in identification of infectious disease patients with fever of unknown origin[J]. Medical Journal of the Chinese People's Armed Police Forces(武警医学), 2020, 31(1): 26-29.
[3] LIU B, ZHOU ZZ, WANG CY, et al.Literature analysis of 422 cases on drug fever[J]. China Pharmaceuticals(中国药业), 2016, 25(21): 74-78.
[4] YUSEF D, GONZALEZ BE, FOSTERN CB, et al.Piperacillin-tazobactam-induced adverse drug events in pediatric patients on outpatient parenteral antimicrobial therapy[J]. Pediatr Infect Dis J, 2017, 36(1): 50-52.
[5] LI M, PAN X.Correlation between serum inflammatory response and stress hormone and immune response in patients with postoperative infection of cesarean section[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)[中华实验和临床感染病杂志(电子版)], 2019, 13(1): 70-75.
[6] CHEN J, ZHAO H, LI RB, et al.Analysis of wound infection after tension-free inguinal hernia repair in adults[J]. Chinese Journal of Hernia and Abdominal Wall Surgery (Electronic Edition)(中华疝和腹壁外科杂志(电子版)), 2019, 13(2): 150-153.
[7] GAO F, LUO L.Analysis of the risk factors of fever after ureteroscopic holmium laser lithotripsy[J]. Chinese Journal of Endourology (Electronic Edition)[中华腔镜泌尿外科杂志(电子版)], 2019, 13(2): 91-94.
[8] WU YS, LU YQ, LIU Q, et al.Clinical analysis of drug fever in 37 AIDS patients[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(18): 1869-1872.
[9] YANG BC, JIANG HP, WANG M, et al.Pharmaceutical care for patients with suspected drug fever induced by ambroxol hydrochloride by clinical pharmacists[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2018, 18(8): 1137-1139.
[10] HU XL, ZHAN H.Systematic evaluation of adverse drug reactions and adverse events of drug fever induced by antimicrobial drugs[J]. Pharmaceutical Journal of Chinese People's Liberation Army(解放军药学学报), 2017, 33(2): 186-189.
[11] ZHU DC, SUN XQ, JIANG HF, et al.Analysis of 48 cases of drug eruptions induced by amoxicillin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 583-588.
[12] YOU CY, XU XL, LI S, et al.140 Cases of severe adverse drug reactions/events in a hospital[J]. Chinese Journal of Pharmaco-vigilance(中国药物警戒), 2020, 17(9): 617-621, 648.
[13] SHI CF, LI J.Pharmaceutical practice for atients with pulmonary infection and drug fever by clinical pharmacists[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2019, 19(2): 238-239.
[14] MAO XG, ZHOU H, ZHANG YY, et al.Study on the drug fever caused byβ-amide antibiotics[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2016, 33(6): 822-824.
[15] HONG Q.One case of anaphylactic shock with hemolytic anemia induced by cedodizime sodium for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(12): 759-761.

临床药师参与1例尿路感染伴药物热患者药学实践

Pharmaceutical care for a patient with urinary tract infection and drug fever

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[3]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[4]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[5]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[6]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.